Compare Global X FTSE Southeast Asia ETF (ASEA) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $294.72 (market cap $7.94B). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ASEA | BIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $339.75 |
52-Week Low | $16.31 | $241.71 |
Market Cap | — | $7.94B |
Enterprise Value | — | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
BIO trades at $296.11, down 0.39% today, with a bullish technical outlook supported by moving averages and a consensus price target of $305. The company reported $2.58B revenue in 2025 with net income of $759.90M, showing a significant turnaround from prior losses. Recent news highlights Nasdaq compliance restoration and participation in industry events, reinforcing operational stability.
BIO presents a positive investment case with strong analyst support (53.85% buy ratings) and improving profitability, though high P/E of 49.27 and recent earnings misses pose valuation and execution risks. Upside potential exists if the company meets future earnings expectations, but investors should monitor debt levels and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
